Cencora, Inc. (NYSE:COR) Shares Purchased by Raymond James Trust N.A.

Raymond James Trust N.A. increased its stake in shares of Cencora, Inc. (NYSE:COR) by 1.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,925 shares of the company’s stock after acquiring an additional 52 shares during the period. Raymond James Trust N.A.’s holdings in Cencora were worth $883,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. New Millennium Group LLC acquired a new stake in Cencora during the second quarter worth about $26,000. MFA Wealth Advisors LLC acquired a new stake in Cencora during the second quarter worth about $30,000. Concord Wealth Partners acquired a new stake in Cencora during the third quarter worth about $30,000. LRI Investments LLC acquired a new stake in Cencora during the first quarter worth about $31,000. Finally, SYSTM Wealth Solutions LLC acquired a new stake in Cencora during the second quarter worth about $36,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 15.80% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $245.02 on Monday. The company has a market cap of $48.28 billion, a PE ratio of 32.63, a price-to-earnings-growth ratio of 1.63 and a beta of 0.44. The stock’s 50 day simple moving average is $233.22 and its 200-day simple moving average is $231.65. Cencora, Inc. has a 1-year low of $195.83 and a 1-year high of $251.56. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is currently 29.29%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on COR. Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Bank of America reiterated a “neutral” rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Wells Fargo & Company increased their price target on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Evercore ISI increased their price target on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.